HC Wainwright Expects Increased Earnings for Fractyl Health

Fractyl Health, Inc. (NASDAQ:GUTS) – HC Wainwright increased their FY2029 earnings estimates for shares of Fractyl Health in a report released on Wednesday, March 25th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of $0.37 per share for the year, up from their previous estimate of $0.31. HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Fractyl Health’s current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Fractyl Health’s FY2030 earnings at $0.94 EPS.

Several other equities analysts also recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Fractyl Health in a research note on Monday, December 29th. Morgan Stanley downgraded shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and cut their price objective for the company from $8.00 to $2.00 in a report on Thursday, January 29th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a research report on Thursday. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $5.40.

Fractyl Health Stock Performance

GUTS opened at $0.45 on Thursday. The company has a debt-to-equity ratio of 3.23, a current ratio of 4.78 and a quick ratio of 4.27. The company has a market capitalization of $71.17 million, a PE ratio of -0.24 and a beta of 1.51. The business has a fifty day simple moving average of $0.71 and a 200 day simple moving average of $1.28. Fractyl Health has a 1 year low of $0.38 and a 1 year high of $3.03.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Tuesday, March 24th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.34.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in GUTS. Jane Street Group LLC acquired a new stake in shares of Fractyl Health in the 2nd quarter valued at $31,000. FNY Investment Advisers LLC acquired a new position in shares of Fractyl Health during the 3rd quarter worth $31,000. Scientech Research LLC acquired a new position in shares of Fractyl Health during the 3rd quarter worth $49,000. Prelude Capital Management LLC bought a new stake in shares of Fractyl Health during the 3rd quarter worth $55,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in shares of Fractyl Health during the 3rd quarter worth $56,000.

Fractyl Health News Summary

Here are the key news stories impacting Fractyl Health this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts (notably FY2026–FY2030) and trimmed near‑term loss estimates while keeping a “Buy” rating and an $8.00 price target — this signals the analyst expects meaningful recovery and eventual profitability, supporting upside versus the current sub‑$1 trade. HC Wainwright analyst note (MarketBeat)
• Positive Sentiment: Canaccord Genuity reaffirmed a “Buy” rating and an $8.00 price target, echoing the bullish analyst narrative and providing additional third‑party validation of the longer‑term thesis. Canaccord reaffirmation (Benzinga)
• Neutral Sentiment: Q4 2025 earnings call transcript is available — the company recently reported an EPS beat for Q4 (reported EPS vs. consensus), which is supportive but investors will focus on follow‑up cadence, cash runway, and clinical/regulatory catalysts. Q4 2025 earnings call transcript (MSN)
• Negative Sentiment: TipRanks flagged “significant compliance risks” under global anti‑corruption and sanctions laws after a new risk disclosure — legal/compliance issues can slow partnerships, delay commercial progress, or increase remediation costs, creating downside risk and adding near‑term uncertainty. Compliance risk disclosure (TipRanks)

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.